The following are excerpts from the newsletter
- Awareness growing about IV
catheter-associated infections due to inappropriate use
- Safety Briefs
- New product, Patanol® could be confused
due to simila rity of name with another product.
- Epoetin alfa labeling updated.
- Institutional disposal of "used" Duragesic®(fentanyl,
Janssen) patches requires greater scrutiny.
- Mix up of strengths of Dilantin® suspension
causes hospital admission for phenytoin toxicity.
- Proposed USP revision will prohibit use of natural
rubber latex in elastomeric closures for injections
due to severe allergies.
- ISMP is eligible for designation under United Way
contributions to support its activities in promoting
medication safety. Please consider remebering us during
your institutions next United Way campaign by including
the ISMP name, address and ID# on your donor choice
Institute for Safe Medication Practices
200 Lakeside Drive, Suite 200, Horsham, PA 19044
- Extra caution needed with U-500
- Initial amiodarone infusions need separate containers
- Use "trigger" alerts to spot ADR trends
- Safety Briefs
- January 22/29, 1997 issue of JAMA includes three articles
on adverse drug event prevention.
- ISMP and International Medical News Group (a division
of WB Saunders Co.) launch columns in Family Practice
News, Internal Medicine News, and OB-Gyn
News about medication errors
- Prescribing via the web? New product may allow secure
- Cedax® a third generation cephalosporin reported
to have been confused by transcriptionists with Cidex®
a germicidal agent.
- Institute for Healthcare Improvement works with ISMP
to develop list of drugs which when improperly used
increase mortality risk.
- Erroneous connection of feeding sets with rigid female
luer connectors on IV sets can have serious and even
- Parke-Davis notifies pharmacy directors that post
marketing surveilance finds confusion regarding current
vial and carton labels for Cerebyx®
- FDA announces new regulations on oral iron tablets
and iron containing supplements.
- Bristol-Myers Squibb Oncology distributes stickers
for slide rules that calculate area under the curve
dosing of Paraplatin® (carboplatin) that indicate
that "calculated creatinine clearance is ONLY an
estimate of GFR"